Pharmaceutical - Markets & Marketing, Teva Pharmaceutical Industries

Filter

Popular Filters

Alexza’s partner Teva launches antipsychotic Adasuve in USA

Alexza’s partner Teva launches antipsychotic Adasuve in USA

04-03-2014

US drug developer Alexza Pharmaceuticals says that its marketing partner, Israel-based generic drugs…

AdasuveAlexza PharmaceuticalMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalTeva Pharmaceutical IndustriesUSA

Teva receives subpoenas over Copaxone and Azilect marketing

Teva receives subpoenas over Copaxone and Azilect marketing

11-02-2014

The US Department of Justice is investigating Israel drugmaker Teva Pharmaceutical Industries’ marketing…

AzilectCopaxoneLegalMarkets & MarketingNeurologicalPharmaceuticalTeva Pharmaceutical Industries

Prostate cancer market to almost double to $8 billion by 2019, says GBI

21-11-2013

The prostate cancer treatment market is forecast to increase from $4.1 billion in 2012 to $8 billion…

Active BiotechAstellas PharmaJohnson & JohnsonMarkets & MarketingOncoGenexOncologyPharmaceuticalTeva Pharmaceutical IndustriesXofigoXtandiZytiga

MS therapeutics market led by Copaxone

17-09-2013

The multiple sclerosis (MS) therapeutics market has been forecast to increase at a compound annual growth…

CopaxoneMarkets & MarketingNeurologicalPharmaceuticalTeva Pharmaceutical Industries

Surge in drug approvals, R&D productivity and investor confidence to drive Pharma expansion through 2018, says Evaluate

25-06-2013

According to the newly-released World Preview 2013 report from market intelligence firm Evaluate, the…

AbbVieBiotechnologyGilead SciencesGlobalHumiraMarkets & MarketingNovartisPfizerPharmaceuticalRegulationResearchsofosbuvirTeva Pharmaceutical Industries

Teva pays $40 million upfront to market Alexza's Adasuve in USA

09-05-2013

The US subsidiary of Israeli generics giant Teva Pharmaceuticals Industries (NYSE: TEVA) has entered…

AdasuveAlexza PharmaceuticalLicensingMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalTeva Pharmaceutical Industries

US FDA approves Lupin's generic version of Teva's Seasonique and Taro's Topicort

15-04-2013

Indian drugmaker Lupin (BSE: 500257) saw its shares gain 2.3% to 659.65 rupees by close of trading on…

DayseeDermatologicalsGenericsLupinMarkets & MarketingNorth AmericaPharmaceuticalRegulationReproductiveSeasoniqueTaro PharmaceuticalsTeva Pharmaceutical IndustriesTopicort

Johnson & Johnson close to settling over Risperdal marketing; SEC probes Teva

06-08-2012

US health care giant Johnson & Johnson (NYSE: JNJ) has reached "an agreement in principle'' with the…

FinancialGenericsInvegaJanssenJohnson & JohnsonLegalMarkets & MarketingNatrecorNorth AmericaPharmaceuticalRisperdalTeva Pharmaceutical Industries

Patient share of Teva/Lundbeck's Azilect for Parkinson's continues to grow

01-08-2012

Through examination of US patient-level claims data, that patient share of Azilect (rasagiline) - from…

AzilectLundbeckMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalTeva Pharmaceutical Industries

EU Commission focus now on Servier and others re-perindopril antitrust issues

31-07-2012

The European Commission has informed French independent pharmaceutical company Servier and several of…

Cardio-vascularEuropeGenericsLegalMarkets & MarketingMylan LaboratoriesPatentsperindoprilPharmaceuticalServierTeva Pharmaceutical Industries

Novartis and Teva announce expansion plans in Russia

05-07-2012

Swiss drug major Novartis (NOVN: VX) has signed an agreement with RT-Biotechprom, one of Russia's largest…

EuropeFinancialGenericsMarkets & MarketingNovartisPharmaceuticalRT-BiotechpromTeva Pharmaceutical Industries

FDA delays once-a-day Prezista approval; finds counterfeit of Teva's Adderall

30-05-2012

US health care giant Johnson & Johnson's (NYSE: JNJ) Janssen Therapeutics division has received a complete…

AdderallAnti-viralsGenericsJanssenJohnson & JohnsonMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalPrezistaRegulationTeva Pharmaceutical Industries

Opportunities for Pharma in narcolepsy

20-02-2012

The narcolepsy therapeutics developmental pipeline is weak, with only six molecules in development, providing…

BioprojectCephalonGenericsMarkets & MarketingNeurologicalNuvigilPharmaceuticalProvigilResearchTeva Pharmaceutical IndustriesUCBXyrem

Watson and Ranbaxy kick off genericization of Lipitor, launching their approved copies in USA

01-12-2011

US generic drug major Watson Pharmaceuticals (NYSE: WPI) was the first to confirm yesterday that it has…

atorvastatinCardio-vascularGenericsLipitorMarkets & MarketingNorth AmericaPfizerPharmaceuticalRanbaxy LaboratoriesTeva Pharmaceutical IndustriesWatson Pharmaceuticals

Recent Gilenya growth appears to be coming from initial trial among late adopters not expanded use among existing prescribers

30-11-2011

After one year on the market, share of Swiss drug major Novartis’ (NOVN: VX) Gilenya (fingolimod),…

AvonexBiogen IdecCopaxoneGilenyaMarkets & MarketingNeurologicalNovartisPharmaceuticalTeva Pharmaceutical IndustriesTysabri

Back to top